AC Immune, a clinical-stage biopharmaceutical precision medicine company for neurodegenerative diseases, announced it’s acquisition of Affiris’s portfolio of therapeutics targeting alphasynuclein (a-syn), notably Affiris PD01, a clinically-validated active vaccine candidate for the treatment
Tags :Linus Zweifel
The shareholder of Odlo has completed the sale of Swiss-based ODLO International and its subsidiaries to Monte Rosa Sports Holding.
